Suppr超能文献

可切除胃腺癌基于临床和病理淋巴结状态的治疗策略比较

Comparison of treatment strategies based on clinical and pathological nodal status in resectable gastric adenocarcinoma.

作者信息

Ajay Pranay S, Mavani Parit T, Sok Caitlin P, Goyal Subir, Switchenko Jeffery M, Gillespie Theresa W, Kooby David A, Kennedy Timothy J, Shah Mihir M

机构信息

Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine, Atlanta, Georgia, USA.

Biostatistics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.

出版信息

J Surg Oncol. 2024 Oct;130(5):1078-1091. doi: 10.1002/jso.27835. Epub 2024 Aug 27.

Abstract

BACKGROUND

To determine the optimal multimodal treatment strategy between perioperative chemotherapy (PEC), postoperative chemoradiation therapy (POCR), and postoperative chemotherapy (POC) in resected gastric cancer (GC) patients based on nodal status.

METHODS

In this retrospective analysis, the National Cancer Database was used to identify resected non-metastatic GC (2006-2016). Patients were stratified by clinical nodal status-negative (cLN-) and positive (cLN+). In patients with cLN- disease who underwent upfront resection and were upstaged to pathological LN+, overall survival (OS) was compared between POC and POCR. In patients with cLN- and cLN+ disease, OS was compared between PEC, POCR, and POC. Kaplan-Meier survival estimate, log-rank test, and multivariable Cox proportional hazards analysis were performed.

RESULTS

We identified 7827 patients (cLN- 4828; cLN+ 2999). On multivariable analysis in patients with cLN- disease who underwent upfront resection (n = 4314) and were upstaged to pLN+ disease (70%), POCR (n = 2300, aHR 0.78, 95% CI 0.70-0.87, p < 0.001) was associated with improved OS compared to POC (n = 907). No significant difference was noted between POCR (n = 766, aHR 1.11, 95% CI 0.88-1.40, p = 0.39) and POC (n = 341) in patients with pLN- disease. On multivariable analysis in all patients with cLN- disease, POCR (n = 3066) was significantly associated with improved OS (aHR 0.84, 95% CI 0.75-0.92, p < 0.01) compared to POC (n = 1248). No significant difference was noted between POCR (aHR 1.0, 95% CI 0.70-1.01, p = 0.958) and PEC (n = 514). These results remained consistent in patients with cLN+ disease (POCR = 1602, POC = 720, PEC = 677).

CONCLUSION

Postoperative chemoradiation is associated with improved survival in GC patients upstaged from clinically node-negative disease to pathologically node-positive disease. Negative clinical nodal disease status is not a reliable indicator of pathological nodal disease.

摘要

背景

基于淋巴结状态确定接受手术切除的胃癌(GC)患者围手术期化疗(PEC)、术后放化疗(POCR)和术后化疗(POC)之间的最佳多模式治疗策略。

方法

在这项回顾性分析中,使用国家癌症数据库识别接受手术切除的非转移性GC患者(2006 - 2016年)。患者按临床淋巴结状态阴性(cLN-)和阳性(cLN+)分层。在接受 upfront 切除且分期上调至病理淋巴结阳性的cLN-疾病患者中,比较POC和POCR的总生存期(OS)。在cLN-和cLN+疾病患者中,比较PEC、POCR和POC的OS。进行了Kaplan-Meier生存估计、对数秩检验和多变量Cox比例风险分析。

结果

我们识别出7827例患者(cLN- 4828例;cLN+ 2999例)。在接受 upfront 切除且分期上调至pLN+疾病(70%)的cLN-疾病患者的多变量分析中(n = 4314),与POC(n = 907)相比,POCR(n = 2300,aHR 0.78,95%CI 0.70 - 0.87,p < 0.001)与OS改善相关。在pLN-疾病患者中,POCR(n = 766,aHR 1.11,95%CI 0.88 - 1.40,p = )和POC(n = 341)之间未观察到显著差异。在所有cLN-疾病患者的多变量分析中,与POC(n = 1248)相比,POCR(n = 30,66)与OS改善显著相关(aHR 0.84,95%CI 0.75 - 0.92,p < 0.01)。POCR(aHR 1.0,95%CI 0.70 - 1.01,p = 0.958)和PEC(n = 514)之间未观察到显著差异。这些结果在cLN+疾病患者中(POCR = 1602,POC = 720,PEC = 677)保持一致。

结论

术后放化疗与从临床淋巴结阴性疾病分期上调至病理淋巴结阳性疾病的GC患者的生存改善相关。临床淋巴结阴性疾病状态不是病理淋巴结疾病的可靠指标。

相似文献

1
Comparison of treatment strategies based on clinical and pathological nodal status in resectable gastric adenocarcinoma.
J Surg Oncol. 2024 Oct;130(5):1078-1091. doi: 10.1002/jso.27835. Epub 2024 Aug 27.
2
Impact of nodal status in determining multimodal treatment strategies in non-cardia gastric cancer.
J Surg Oncol. 2023 Aug;128(2):242-253. doi: 10.1002/jso.27297. Epub 2023 Apr 28.
3
Identifying the optimal treatment strategy in patients with resectable non-cardia gastric cancer.
Surg Endosc. 2024 Jan;38(1):136-147. doi: 10.1007/s00464-023-10515-x. Epub 2023 Nov 7.
4
Does non-metastatic gastric cancer of the cardia warrant a different treatment strategy?
J Surg Oncol. 2023 Aug;128(2):231-241. doi: 10.1002/jso.27276. Epub 2023 Apr 10.
6
7
National Trends in Multimodality Therapy for Locally Advanced Gastric Cancer.
J Surg Res. 2019 May;237:41-49. doi: 10.1016/j.jss.2018.12.026. Epub 2019 Jan 23.
9
Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy.
Surgery. 2017 Aug;162(2):285-294. doi: 10.1016/j.surg.2017.03.023. Epub 2017 May 31.
10
Staging accuracy in patients with clinical T2N0 gastric cancer: Implications for treatment sequencing.
Surgery. 2025 Mar;179:108796. doi: 10.1016/j.surg.2024.07.055. Epub 2024 Oct 2.

本文引用的文献

1
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw. 2022 Feb;20(2):167-192. doi: 10.6004/jnccn.2022.0008.
3
The Discordance of Clinical and Pathologic Staging in Locally Advanced Gastric Adenocarcinoma.
J Gastrointest Surg. 2021 Jun;25(6):1363-1369. doi: 10.1007/s11605-021-04993-4. Epub 2021 Apr 12.
9
Number of Lymph Nodes Removed and Survival after Gastric Cancer Resection: An Analysis from the US Gastric Cancer Collaborative.
J Am Coll Surg. 2015 Aug;221(2):291-9. doi: 10.1016/j.jamcollsurg.2015.04.024. Epub 2015 May 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验